These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 17291359)

  • 21. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
    Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
    J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
    Evans KR; Sills T; Wunderlich GR; McDonald HP
    J Psychiatr Res; 2004; 38(4):437-44. PubMed ID: 15203296
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Live attenuated human rotavirus vaccine, RIX4414, provides clinical protection in infants against rotavirus strains with and without shared G and P genotypes: integrated analysis of randomized controlled trials.
    De Vos B; Han HH; Bouckenooghe A; Debrus S; Gillard P; Ward R; Cheuvart B
    Pediatr Infect Dis J; 2009 Apr; 28(4):261-6. PubMed ID: 19289978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Field assays with anti-malarial vaccines: phase III protocols.
    Sanchez T
    Rev Inst Med Trop Sao Paulo; 1992 Apr; 34 Suppl 9():S24-7. PubMed ID: 1340629
    [No Abstract]   [Full Text] [Related]  

  • 27. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Using instrumental variables to disentangle treatment and placebo effects in blinded and unblinded randomized clinical trials influenced by unmeasured confounders.
    Chaibub Neto E
    Sci Rep; 2016 Nov; 6():37154. PubMed ID: 27869205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statistical aspects of fish vaccination trials.
    Jarp J; Tverdal A
    Dev Biol Stand; 1997; 90():311-20. PubMed ID: 9270859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chop-lump tests for vaccine trials.
    Follmann D; Fay MP; Proschan M
    Biometrics; 2009 Sep; 65(3):885-93. PubMed ID: 19210727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simple adjustments for randomized trials with nonrandomly missing or censored outcomes arising from informative covariates.
    Baker SG; Fitzmaurice GM; Freedman LS; Kramer BS
    Biostatistics; 2006 Jan; 7(1):29-40. PubMed ID: 15923407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method to estimate the variance of an endpoint from an on-going blinded trial.
    Xing B; Ganju J
    Stat Med; 2005 Jun; 24(12):1807-14. PubMed ID: 15803440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomizing research participants: promoting balance and concealment in small samples.
    Matthews EE; Cook PF; Terada M; Aloia MS
    Res Nurs Health; 2010 Jun; 33(3):243-53. PubMed ID: 20499394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field.
    Halloran ME; Longini IM; Haber MJ; Struchiner CJ; Brunet RC
    Stat Med; 1994 Feb; 13(4):357-77. PubMed ID: 8177986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reporting of treatment effects from randomized trials: a plea for multivariable risk ratios.
    Groenwold RH; Moons KG; Peelen LM; Knol MJ; Hoes AW
    Contemp Clin Trials; 2011 May; 32(3):399-402. PubMed ID: 21195797
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Revisiting the level of evidence in randomized controlled clinical trials: A simulation approach.
    Bajard A; Chabaud S; Pérol D; Boissel JP; Nony P
    Contemp Clin Trials; 2009 Sep; 30(5):400-10. PubMed ID: 19576298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infectious Diseases. Ebola vaccine trials raise ethical issues.
    Cohen J; Kupferschmidt K
    Science; 2014 Oct; 346(6207):289-90. PubMed ID: 25324364
    [No Abstract]   [Full Text] [Related]  

  • 40. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
    Fleming TR; Krause PR; Nason M; Longini IM; Henao-Restrepo AM
    Clin Trials; 2021 Jun; 18(3):335-342. PubMed ID: 33535811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.